Skip to main content
PharmGen Science, Inc. logo

PharmGen Science, Inc. — Investor Relations & Filings

Ticker · 004720 ISIN · KR7004720009 KO Manufacturing
Open in API
Filings indexed 296 across all filing types
Latest filing 2019-03-27 Board/Management Inform…
Country KR South Korea
Listing KO 004720

About PharmGen Science, Inc.

http://www.pharmgenscience.com/en/

PharmGen Science, Inc. is a pharmaceutical company engaged in the research, development, production, and sale of medicaments. The company's portfolio encompasses a range of prescription (ETC) and over-the-counter (OTC) drugs, including analgesics, antibiotics, and anti-inflammatory agents. A key strategic focus for the company is the discovery and development of novel drugs for gastrointestinal (GI) disorders. PharmGen Science aims to provide integrated pharmaceutical solutions by leveraging its diverse infrastructure and global network.

Recent filings

Filing Released Lang Actions
대표이사(대표집행임원)변경(안내공시)
Board/Management Information Classification · 100% confidence The document is a formal announcement regarding the change of the company's CEO (Representative Director). It lists the names of the outgoing and incoming directors, the reason for the change (resignation and new appointment), the effective date, and the professional biographies of the new appointees. This aligns perfectly with the definition for Board/Management Information (MANG).
2019-03-27 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a formal announcement titled '감사보고서 제출' (Submission of Audit Report) by Woori-dle Pharmaceutical. It provides a summary of the audit opinion (unqualified/appropriate) and key financial data (assets, liabilities, revenue, profit) for the fiscal year ending 2018-12-31. While it contains financial data, it is a regulatory disclosure announcing the completion and submission of the audit report to the exchange, rather than the full audit report document itself. According to the 'Menu vs Meal' rule, this is a report publication announcement. FY 2018
2019-03-19 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for '우리들제약'. It outlines the date, location, and agenda items (such as financial statement approval, director appointments, and remuneration limits). This type of document is sent to shareholders to provide information and request votes for an upcoming meeting, which fits the definition of a Proxy Solicitation & Information Statement.
2019-03-07 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Wooridul Pharmaceutical Co., Ltd. It contains the agenda for the 53rd Annual General Meeting, including reports on financial statements, board activities, and governance. While it contains financial data (as required by Korean law for shareholder meeting notices), it is fundamentally a proxy solicitation and meeting notice document sent to shareholders to inform them of the meeting and request their participation/voting. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2019-03-07 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a 'Proxy Solicitation' (참고서류) filed by Woori-dle Pharmaceutical Co., Ltd. It contains information regarding the upcoming 53rd Annual General Meeting (AGM), including the purpose of the meeting, director/management information, and financial statements (balance sheet, income statement, etc.) to be approved by shareholders. It is a formal document sent to shareholders to provide information and request votes for the meeting, which fits the definition of a Proxy Solicitation & Information Statement (PSI).
2019-03-07 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This type of filing is a standard regulatory requirement for company insiders (directors/executives) to disclose their shareholdings and changes therein. Based on the provided definitions, this falls under 'Director's Dealing' (DIRS), which covers reports of personal share transactions by company directors and executives.
2019-01-08 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.